nodes	percent_of_prediction	percent_of_DWPC	metapath
Propafenone—Quinapril—Lisinopril—systemic scleroderma	0.216	0.512	CrCrCtD
Propafenone—Benazepril—Lisinopril—systemic scleroderma	0.206	0.488	CrCrCtD
Propafenone—CYP2C8—Mometasone—systemic scleroderma	0.076	0.205	CbGbCtD
Propafenone—CYP1A2—Pentoxifylline—systemic scleroderma	0.0397	0.107	CbGbCtD
Propafenone—CYP1A2—Leflunomide—systemic scleroderma	0.0379	0.102	CbGbCtD
Propafenone—ABCB1—Lisinopril—systemic scleroderma	0.0348	0.0938	CbGbCtD
Propafenone—CYP2C9—Leflunomide—systemic scleroderma	0.0342	0.0922	CbGbCtD
Propafenone—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0303	0.0817	CbGbCtD
Propafenone—ABCB1—Captopril—systemic scleroderma	0.026	0.0702	CbGbCtD
Propafenone—CYP2D6—Captopril—systemic scleroderma	0.0245	0.0662	CbGbCtD
Propafenone—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0205	0.0553	CbGbCtD
Propafenone—ABCB1—Prednisone—systemic scleroderma	0.0164	0.0442	CbGbCtD
Propafenone—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0123	0.0331	CbGbCtD
Propafenone—CYP3A4—Prednisone—systemic scleroderma	0.00981	0.0265	CbGbCtD
Propafenone—ABCB1—Methotrexate—systemic scleroderma	0.00822	0.0222	CbGbCtD
Propafenone—Quinapril—ACE—systemic scleroderma	0.000929	0.535	CrCbGaD
Propafenone—Benazepril—ACE—systemic scleroderma	0.000808	0.465	CrCbGaD
Propafenone—Hyperglycaemia—Prednisone—systemic scleroderma	9.95e-05	0.000482	CcSEcCtD
Propafenone—Cough—Mycophenolate mofetil—systemic scleroderma	9.89e-05	0.00048	CcSEcCtD
Propafenone—Hypotension—Lisinopril—systemic scleroderma	9.87e-05	0.000478	CcSEcCtD
Propafenone—Dizziness—Captopril—systemic scleroderma	9.86e-05	0.000478	CcSEcCtD
Propafenone—Liver function test abnormal—Methotrexate—systemic scleroderma	9.84e-05	0.000477	CcSEcCtD
Propafenone—Convulsion—Mycophenolate mofetil—systemic scleroderma	9.82e-05	0.000476	CcSEcCtD
Propafenone—Depression—Prednisone—systemic scleroderma	9.8e-05	0.000475	CcSEcCtD
Propafenone—Hypertension—Mycophenolate mofetil—systemic scleroderma	9.79e-05	0.000475	CcSEcCtD
Propafenone—Urticaria—Leflunomide—systemic scleroderma	9.76e-05	0.000473	CcSEcCtD
Propafenone—Abdominal pain—Leflunomide—systemic scleroderma	9.71e-05	0.000471	CcSEcCtD
Propafenone—Body temperature increased—Leflunomide—systemic scleroderma	9.71e-05	0.000471	CcSEcCtD
Propafenone—Feeling abnormal—Mycophenolic acid—systemic scleroderma	9.66e-05	0.000468	CcSEcCtD
Propafenone—Chest pain—Mycophenolate mofetil—systemic scleroderma	9.65e-05	0.000468	CcSEcCtD
Propafenone—Myalgia—Mycophenolate mofetil—systemic scleroderma	9.65e-05	0.000468	CcSEcCtD
Propafenone—Neuropathy peripheral—Prednisone—systemic scleroderma	9.64e-05	0.000467	CcSEcCtD
Propafenone—Breast disorder—Methotrexate—systemic scleroderma	9.64e-05	0.000467	CcSEcCtD
Propafenone—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	9.62e-05	0.000467	CcSEcCtD
Propafenone—Anxiety—Mycophenolate mofetil—systemic scleroderma	9.62e-05	0.000466	CcSEcCtD
Propafenone—Hypersensitivity—Azathioprine—systemic scleroderma	9.59e-05	0.000465	CcSEcCtD
Propafenone—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	9.59e-05	0.000465	CcSEcCtD
Propafenone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	9.58e-05	0.000465	CcSEcCtD
Propafenone—Insomnia—Lisinopril—systemic scleroderma	9.55e-05	0.000463	CcSEcCtD
Propafenone—Discomfort—Mycophenolate mofetil—systemic scleroderma	9.53e-05	0.000462	CcSEcCtD
Propafenone—Paraesthesia—Lisinopril—systemic scleroderma	9.48e-05	0.00046	CcSEcCtD
Propafenone—Vomiting—Captopril—systemic scleroderma	9.48e-05	0.00046	CcSEcCtD
Propafenone—Dry mouth—Mycophenolate mofetil—systemic scleroderma	9.44e-05	0.000458	CcSEcCtD
Propafenone—Dyspnoea—Lisinopril—systemic scleroderma	9.41e-05	0.000457	CcSEcCtD
Propafenone—Rash—Captopril—systemic scleroderma	9.4e-05	0.000456	CcSEcCtD
Propafenone—Dermatitis—Captopril—systemic scleroderma	9.39e-05	0.000455	CcSEcCtD
Propafenone—Somnolence—Lisinopril—systemic scleroderma	9.39e-05	0.000455	CcSEcCtD
Propafenone—Headache—Captopril—systemic scleroderma	9.34e-05	0.000453	CcSEcCtD
Propafenone—Confusional state—Mycophenolate mofetil—systemic scleroderma	9.33e-05	0.000452	CcSEcCtD
Propafenone—Dyspepsia—Lisinopril—systemic scleroderma	9.29e-05	0.000451	CcSEcCtD
Propafenone—Abdominal pain—Mycophenolic acid—systemic scleroderma	9.27e-05	0.000449	CcSEcCtD
Propafenone—Body temperature increased—Mycophenolic acid—systemic scleroderma	9.27e-05	0.000449	CcSEcCtD
Propafenone—Oedema—Mycophenolate mofetil—systemic scleroderma	9.25e-05	0.000449	CcSEcCtD
Propafenone—Infection—Mycophenolate mofetil—systemic scleroderma	9.19e-05	0.000446	CcSEcCtD
Propafenone—Decreased appetite—Lisinopril—systemic scleroderma	9.18e-05	0.000445	CcSEcCtD
Propafenone—Eosinophilia—Methotrexate—systemic scleroderma	9.12e-05	0.000443	CcSEcCtD
Propafenone—Gastrointestinal disorder—Lisinopril—systemic scleroderma	9.12e-05	0.000442	CcSEcCtD
Propafenone—Fatigue—Lisinopril—systemic scleroderma	9.1e-05	0.000441	CcSEcCtD
Propafenone—Shock—Mycophenolate mofetil—systemic scleroderma	9.1e-05	0.000441	CcSEcCtD
Propafenone—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	9.07e-05	0.00044	CcSEcCtD
Propafenone—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	9.06e-05	0.000439	CcSEcCtD
Propafenone—Hypersensitivity—Leflunomide—systemic scleroderma	9.05e-05	0.000439	CcSEcCtD
Propafenone—Pancreatitis—Methotrexate—systemic scleroderma	9.04e-05	0.000438	CcSEcCtD
Propafenone—Constipation—Lisinopril—systemic scleroderma	9.03e-05	0.000438	CcSEcCtD
Propafenone—Pain—Lisinopril—systemic scleroderma	9.03e-05	0.000438	CcSEcCtD
Propafenone—Tachycardia—Mycophenolate mofetil—systemic scleroderma	9.03e-05	0.000438	CcSEcCtD
Propafenone—Skin disorder—Mycophenolate mofetil—systemic scleroderma	8.99e-05	0.000436	CcSEcCtD
Propafenone—Bradycardia—Prednisone—systemic scleroderma	8.99e-05	0.000436	CcSEcCtD
Propafenone—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	8.94e-05	0.000434	CcSEcCtD
Propafenone—Diarrhoea—Azathioprine—systemic scleroderma	8.9e-05	0.000432	CcSEcCtD
Propafenone—Haemoglobin—Prednisone—systemic scleroderma	8.87e-05	0.00043	CcSEcCtD
Propafenone—Nausea—Captopril—systemic scleroderma	8.86e-05	0.000429	CcSEcCtD
Propafenone—Haemorrhage—Prednisone—systemic scleroderma	8.83e-05	0.000428	CcSEcCtD
Propafenone—Anorexia—Mycophenolate mofetil—systemic scleroderma	8.82e-05	0.000428	CcSEcCtD
Propafenone—Asthenia—Leflunomide—systemic scleroderma	8.82e-05	0.000428	CcSEcCtD
Propafenone—Feeling abnormal—Lisinopril—systemic scleroderma	8.7e-05	0.000422	CcSEcCtD
Propafenone—Pruritus—Leflunomide—systemic scleroderma	8.69e-05	0.000422	CcSEcCtD
Propafenone—Connective tissue disorder—Prednisone—systemic scleroderma	8.67e-05	0.000421	CcSEcCtD
Propafenone—Hypotension—Mycophenolate mofetil—systemic scleroderma	8.64e-05	0.000419	CcSEcCtD
Propafenone—Gastrointestinal pain—Lisinopril—systemic scleroderma	8.63e-05	0.000419	CcSEcCtD
Propafenone—Dysuria—Methotrexate—systemic scleroderma	8.62e-05	0.000418	CcSEcCtD
Propafenone—Dizziness—Azathioprine—systemic scleroderma	8.6e-05	0.000417	CcSEcCtD
Propafenone—Upper respiratory tract infection—Methotrexate—systemic scleroderma	8.56e-05	0.000415	CcSEcCtD
Propafenone—Erectile dysfunction—Methotrexate—systemic scleroderma	8.49e-05	0.000412	CcSEcCtD
Propafenone—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	8.43e-05	0.000409	CcSEcCtD
Propafenone—Asthenia—Mycophenolic acid—systemic scleroderma	8.41e-05	0.000408	CcSEcCtD
Propafenone—Diarrhoea—Leflunomide—systemic scleroderma	8.41e-05	0.000408	CcSEcCtD
Propafenone—Urticaria—Lisinopril—systemic scleroderma	8.39e-05	0.000407	CcSEcCtD
Propafenone—Insomnia—Mycophenolate mofetil—systemic scleroderma	8.37e-05	0.000406	CcSEcCtD
Propafenone—Abdominal pain—Lisinopril—systemic scleroderma	8.35e-05	0.000405	CcSEcCtD
Propafenone—Body temperature increased—Lisinopril—systemic scleroderma	8.35e-05	0.000405	CcSEcCtD
Propafenone—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	8.31e-05	0.000403	CcSEcCtD
Propafenone—Pruritus—Mycophenolic acid—systemic scleroderma	8.29e-05	0.000402	CcSEcCtD
Propafenone—Vomiting—Azathioprine—systemic scleroderma	8.27e-05	0.000401	CcSEcCtD
Propafenone—Eye disorder—Prednisone—systemic scleroderma	8.25e-05	0.0004	CcSEcCtD
Propafenone—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	8.25e-05	0.0004	CcSEcCtD
Propafenone—Somnolence—Mycophenolate mofetil—systemic scleroderma	8.22e-05	0.000399	CcSEcCtD
Propafenone—Drowsiness—Methotrexate—systemic scleroderma	8.22e-05	0.000398	CcSEcCtD
Propafenone—Infestation—Methotrexate—systemic scleroderma	8.22e-05	0.000398	CcSEcCtD
Propafenone—Infestation NOS—Methotrexate—systemic scleroderma	8.22e-05	0.000398	CcSEcCtD
Propafenone—Rash—Azathioprine—systemic scleroderma	8.2e-05	0.000398	CcSEcCtD
Propafenone—Dermatitis—Azathioprine—systemic scleroderma	8.2e-05	0.000398	CcSEcCtD
Propafenone—Depression—Methotrexate—systemic scleroderma	8.19e-05	0.000397	CcSEcCtD
Propafenone—Flushing—Prednisone—systemic scleroderma	8.19e-05	0.000397	CcSEcCtD
Propafenone—Headache—Azathioprine—systemic scleroderma	8.15e-05	0.000395	CcSEcCtD
Propafenone—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	8.14e-05	0.000395	CcSEcCtD
Propafenone—Dizziness—Leflunomide—systemic scleroderma	8.13e-05	0.000394	CcSEcCtD
Propafenone—Renal failure—Methotrexate—systemic scleroderma	8.08e-05	0.000392	CcSEcCtD
Propafenone—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	8.04e-05	0.00039	CcSEcCtD
Propafenone—Diarrhoea—Mycophenolic acid—systemic scleroderma	8.02e-05	0.000389	CcSEcCtD
Propafenone—Stomatitis—Methotrexate—systemic scleroderma	8.01e-05	0.000388	CcSEcCtD
Propafenone—Angiopathy—Prednisone—systemic scleroderma	8.01e-05	0.000388	CcSEcCtD
Propafenone—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	7.99e-05	0.000387	CcSEcCtD
Propafenone—Immune system disorder—Prednisone—systemic scleroderma	7.97e-05	0.000387	CcSEcCtD
Propafenone—Pain—Mycophenolate mofetil—systemic scleroderma	7.91e-05	0.000384	CcSEcCtD
Propafenone—Constipation—Mycophenolate mofetil—systemic scleroderma	7.91e-05	0.000384	CcSEcCtD
Propafenone—Arrhythmia—Prednisone—systemic scleroderma	7.88e-05	0.000382	CcSEcCtD
Propafenone—Haematuria—Methotrexate—systemic scleroderma	7.83e-05	0.00038	CcSEcCtD
Propafenone—Vomiting—Leflunomide—systemic scleroderma	7.81e-05	0.000379	CcSEcCtD
Propafenone—Alopecia—Prednisone—systemic scleroderma	7.8e-05	0.000378	CcSEcCtD
Propafenone—Hypersensitivity—Lisinopril—systemic scleroderma	7.78e-05	0.000377	CcSEcCtD
Propafenone—Hepatobiliary disease—Methotrexate—systemic scleroderma	7.77e-05	0.000377	CcSEcCtD
Propafenone—Dizziness—Mycophenolic acid—systemic scleroderma	7.75e-05	0.000376	CcSEcCtD
Propafenone—Epistaxis—Methotrexate—systemic scleroderma	7.75e-05	0.000376	CcSEcCtD
Propafenone—Rash—Leflunomide—systemic scleroderma	7.75e-05	0.000376	CcSEcCtD
Propafenone—Dermatitis—Leflunomide—systemic scleroderma	7.74e-05	0.000375	CcSEcCtD
Propafenone—Mental disorder—Prednisone—systemic scleroderma	7.73e-05	0.000375	CcSEcCtD
Propafenone—Nausea—Azathioprine—systemic scleroderma	7.73e-05	0.000375	CcSEcCtD
Propafenone—Headache—Leflunomide—systemic scleroderma	7.7e-05	0.000373	CcSEcCtD
Propafenone—Erythema—Prednisone—systemic scleroderma	7.68e-05	0.000373	CcSEcCtD
Propafenone—Malnutrition—Prednisone—systemic scleroderma	7.68e-05	0.000373	CcSEcCtD
Propafenone—Agranulocytosis—Methotrexate—systemic scleroderma	7.67e-05	0.000372	CcSEcCtD
Propafenone—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	7.62e-05	0.00037	CcSEcCtD
Propafenone—Asthenia—Lisinopril—systemic scleroderma	7.58e-05	0.000367	CcSEcCtD
Propafenone—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	7.56e-05	0.000367	CcSEcCtD
Propafenone—Pruritus—Lisinopril—systemic scleroderma	7.47e-05	0.000362	CcSEcCtD
Propafenone—Vomiting—Mycophenolic acid—systemic scleroderma	7.45e-05	0.000361	CcSEcCtD
Propafenone—Haemoglobin—Methotrexate—systemic scleroderma	7.41e-05	0.00036	CcSEcCtD
Propafenone—Rash—Mycophenolic acid—systemic scleroderma	7.39e-05	0.000358	CcSEcCtD
Propafenone—Dermatitis—Mycophenolic acid—systemic scleroderma	7.38e-05	0.000358	CcSEcCtD
Propafenone—Haemorrhage—Methotrexate—systemic scleroderma	7.38e-05	0.000358	CcSEcCtD
Propafenone—Hepatitis—Methotrexate—systemic scleroderma	7.38e-05	0.000358	CcSEcCtD
Propafenone—Urticaria—Mycophenolate mofetil—systemic scleroderma	7.35e-05	0.000356	CcSEcCtD
Propafenone—Headache—Mycophenolic acid—systemic scleroderma	7.34e-05	0.000356	CcSEcCtD
Propafenone—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	7.31e-05	0.000355	CcSEcCtD
Propafenone—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	7.31e-05	0.000355	CcSEcCtD
Propafenone—Nausea—Leflunomide—systemic scleroderma	7.3e-05	0.000354	CcSEcCtD
Propafenone—Urinary tract disorder—Methotrexate—systemic scleroderma	7.28e-05	0.000353	CcSEcCtD
Propafenone—Vision blurred—Prednisone—systemic scleroderma	7.24e-05	0.000351	CcSEcCtD
Propafenone—Urethral disorder—Methotrexate—systemic scleroderma	7.23e-05	0.000351	CcSEcCtD
Propafenone—Diarrhoea—Lisinopril—systemic scleroderma	7.22e-05	0.00035	CcSEcCtD
Propafenone—Ill-defined disorder—Prednisone—systemic scleroderma	7.13e-05	0.000346	CcSEcCtD
Propafenone—Visual impairment—Methotrexate—systemic scleroderma	7.11e-05	0.000345	CcSEcCtD
Propafenone—Anaemia—Prednisone—systemic scleroderma	7.1e-05	0.000344	CcSEcCtD
Propafenone—Dizziness—Lisinopril—systemic scleroderma	6.98e-05	0.000339	CcSEcCtD
Propafenone—Nausea—Mycophenolic acid—systemic scleroderma	6.96e-05	0.000338	CcSEcCtD
Propafenone—Malaise—Prednisone—systemic scleroderma	6.93e-05	0.000336	CcSEcCtD
Propafenone—Vertigo—Prednisone—systemic scleroderma	6.9e-05	0.000335	CcSEcCtD
Propafenone—Eye disorder—Methotrexate—systemic scleroderma	6.89e-05	0.000334	CcSEcCtD
Propafenone—Syncope—Prednisone—systemic scleroderma	6.89e-05	0.000334	CcSEcCtD
Propafenone—Tinnitus—Methotrexate—systemic scleroderma	6.88e-05	0.000334	CcSEcCtD
Propafenone—Cardiac disorder—Methotrexate—systemic scleroderma	6.85e-05	0.000332	CcSEcCtD
Propafenone—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	6.82e-05	0.000331	CcSEcCtD
Propafenone—Loss of consciousness—Prednisone—systemic scleroderma	6.75e-05	0.000328	CcSEcCtD
Propafenone—Vomiting—Lisinopril—systemic scleroderma	6.71e-05	0.000326	CcSEcCtD
Propafenone—Angiopathy—Methotrexate—systemic scleroderma	6.69e-05	0.000325	CcSEcCtD
Propafenone—Immune system disorder—Methotrexate—systemic scleroderma	6.66e-05	0.000323	CcSEcCtD
Propafenone—Rash—Lisinopril—systemic scleroderma	6.66e-05	0.000323	CcSEcCtD
Propafenone—Convulsion—Prednisone—systemic scleroderma	6.66e-05	0.000323	CcSEcCtD
Propafenone—Dermatitis—Lisinopril—systemic scleroderma	6.65e-05	0.000323	CcSEcCtD
Propafenone—Mediastinal disorder—Methotrexate—systemic scleroderma	6.65e-05	0.000322	CcSEcCtD
Propafenone—Asthenia—Mycophenolate mofetil—systemic scleroderma	6.64e-05	0.000322	CcSEcCtD
Propafenone—Hypertension—Prednisone—systemic scleroderma	6.63e-05	0.000322	CcSEcCtD
Propafenone—Headache—Lisinopril—systemic scleroderma	6.61e-05	0.000321	CcSEcCtD
Propafenone—Pruritus—Mycophenolate mofetil—systemic scleroderma	6.54e-05	0.000317	CcSEcCtD
Propafenone—Myalgia—Prednisone—systemic scleroderma	6.54e-05	0.000317	CcSEcCtD
Propafenone—Anxiety—Prednisone—systemic scleroderma	6.52e-05	0.000316	CcSEcCtD
Propafenone—Alopecia—Methotrexate—systemic scleroderma	6.52e-05	0.000316	CcSEcCtD
Propafenone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	6.5e-05	0.000315	CcSEcCtD
Propafenone—Discomfort—Prednisone—systemic scleroderma	6.46e-05	0.000313	CcSEcCtD
Propafenone—Mental disorder—Methotrexate—systemic scleroderma	6.46e-05	0.000313	CcSEcCtD
Propafenone—Erythema—Methotrexate—systemic scleroderma	6.42e-05	0.000311	CcSEcCtD
Propafenone—Malnutrition—Methotrexate—systemic scleroderma	6.42e-05	0.000311	CcSEcCtD
Propafenone—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	6.33e-05	0.000307	CcSEcCtD
Propafenone—Dysgeusia—Methotrexate—systemic scleroderma	6.29e-05	0.000305	CcSEcCtD
Propafenone—Nausea—Lisinopril—systemic scleroderma	6.27e-05	0.000304	CcSEcCtD
Propafenone—Oedema—Prednisone—systemic scleroderma	6.27e-05	0.000304	CcSEcCtD
Propafenone—Infection—Prednisone—systemic scleroderma	6.23e-05	0.000302	CcSEcCtD
Propafenone—Shock—Prednisone—systemic scleroderma	6.17e-05	0.000299	CcSEcCtD
Propafenone—Nervous system disorder—Prednisone—systemic scleroderma	6.15e-05	0.000298	CcSEcCtD
Propafenone—Tachycardia—Prednisone—systemic scleroderma	6.12e-05	0.000297	CcSEcCtD
Propafenone—Dizziness—Mycophenolate mofetil—systemic scleroderma	6.12e-05	0.000297	CcSEcCtD
Propafenone—Skin disorder—Prednisone—systemic scleroderma	6.09e-05	0.000295	CcSEcCtD
Propafenone—Hyperhidrosis—Prednisone—systemic scleroderma	6.06e-05	0.000294	CcSEcCtD
Propafenone—Vision blurred—Methotrexate—systemic scleroderma	6.05e-05	0.000293	CcSEcCtD
Propafenone—Anorexia—Prednisone—systemic scleroderma	5.98e-05	0.00029	CcSEcCtD
Propafenone—Ill-defined disorder—Methotrexate—systemic scleroderma	5.96e-05	0.000289	CcSEcCtD
Propafenone—Anaemia—Methotrexate—systemic scleroderma	5.93e-05	0.000288	CcSEcCtD
Propafenone—Vomiting—Mycophenolate mofetil—systemic scleroderma	5.88e-05	0.000285	CcSEcCtD
Propafenone—Rash—Mycophenolate mofetil—systemic scleroderma	5.83e-05	0.000283	CcSEcCtD
Propafenone—Dermatitis—Mycophenolate mofetil—systemic scleroderma	5.83e-05	0.000283	CcSEcCtD
Propafenone—Headache—Mycophenolate mofetil—systemic scleroderma	5.8e-05	0.000281	CcSEcCtD
Propafenone—Malaise—Methotrexate—systemic scleroderma	5.79e-05	0.000281	CcSEcCtD
Propafenone—Vertigo—Methotrexate—systemic scleroderma	5.77e-05	0.00028	CcSEcCtD
Propafenone—Leukopenia—Methotrexate—systemic scleroderma	5.75e-05	0.000279	CcSEcCtD
Propafenone—Musculoskeletal discomfort—Prednisone—systemic scleroderma	5.71e-05	0.000277	CcSEcCtD
Propafenone—Insomnia—Prednisone—systemic scleroderma	5.67e-05	0.000275	CcSEcCtD
Propafenone—Paraesthesia—Prednisone—systemic scleroderma	5.63e-05	0.000273	CcSEcCtD
Propafenone—Cough—Methotrexate—systemic scleroderma	5.6e-05	0.000272	CcSEcCtD
Propafenone—Convulsion—Methotrexate—systemic scleroderma	5.56e-05	0.00027	CcSEcCtD
Propafenone—Dyspepsia—Prednisone—systemic scleroderma	5.52e-05	0.000268	CcSEcCtD
Propafenone—Nausea—Mycophenolate mofetil—systemic scleroderma	5.49e-05	0.000266	CcSEcCtD
Propafenone—Myalgia—Methotrexate—systemic scleroderma	5.47e-05	0.000265	CcSEcCtD
Propafenone—Chest pain—Methotrexate—systemic scleroderma	5.47e-05	0.000265	CcSEcCtD
Propafenone—Decreased appetite—Prednisone—systemic scleroderma	5.45e-05	0.000264	CcSEcCtD
Propafenone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	5.43e-05	0.000263	CcSEcCtD
Propafenone—Fatigue—Prednisone—systemic scleroderma	5.41e-05	0.000262	CcSEcCtD
Propafenone—Discomfort—Methotrexate—systemic scleroderma	5.4e-05	0.000262	CcSEcCtD
Propafenone—Constipation—Prednisone—systemic scleroderma	5.36e-05	0.00026	CcSEcCtD
Propafenone—Confusional state—Methotrexate—systemic scleroderma	5.28e-05	0.000256	CcSEcCtD
Propafenone—Infection—Methotrexate—systemic scleroderma	5.21e-05	0.000252	CcSEcCtD
Propafenone—Feeling abnormal—Prednisone—systemic scleroderma	5.17e-05	0.000251	CcSEcCtD
Propafenone—Nervous system disorder—Methotrexate—systemic scleroderma	5.14e-05	0.000249	CcSEcCtD
Propafenone—Thrombocytopenia—Methotrexate—systemic scleroderma	5.13e-05	0.000249	CcSEcCtD
Propafenone—Gastrointestinal pain—Prednisone—systemic scleroderma	5.13e-05	0.000249	CcSEcCtD
Propafenone—Skin disorder—Methotrexate—systemic scleroderma	5.09e-05	0.000247	CcSEcCtD
Propafenone—Hyperhidrosis—Methotrexate—systemic scleroderma	5.07e-05	0.000246	CcSEcCtD
Propafenone—Anorexia—Methotrexate—systemic scleroderma	5e-05	0.000242	CcSEcCtD
Propafenone—Urticaria—Prednisone—systemic scleroderma	4.98e-05	0.000242	CcSEcCtD
Propafenone—Abdominal pain—Prednisone—systemic scleroderma	4.96e-05	0.00024	CcSEcCtD
Propafenone—Body temperature increased—Prednisone—systemic scleroderma	4.96e-05	0.00024	CcSEcCtD
Propafenone—Hypotension—Methotrexate—systemic scleroderma	4.9e-05	0.000237	CcSEcCtD
Propafenone—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	4.77e-05	0.000232	CcSEcCtD
Propafenone—Insomnia—Methotrexate—systemic scleroderma	4.74e-05	0.00023	CcSEcCtD
Propafenone—Paraesthesia—Methotrexate—systemic scleroderma	4.71e-05	0.000228	CcSEcCtD
Propafenone—Dyspnoea—Methotrexate—systemic scleroderma	4.67e-05	0.000227	CcSEcCtD
Propafenone—Somnolence—Methotrexate—systemic scleroderma	4.66e-05	0.000226	CcSEcCtD
Propafenone—Hypersensitivity—Prednisone—systemic scleroderma	4.62e-05	0.000224	CcSEcCtD
Propafenone—Dyspepsia—Methotrexate—systemic scleroderma	4.61e-05	0.000224	CcSEcCtD
Propafenone—Decreased appetite—Methotrexate—systemic scleroderma	4.56e-05	0.000221	CcSEcCtD
Propafenone—Gastrointestinal disorder—Methotrexate—systemic scleroderma	4.52e-05	0.000219	CcSEcCtD
Propafenone—Fatigue—Methotrexate—systemic scleroderma	4.52e-05	0.000219	CcSEcCtD
Propafenone—Asthenia—Prednisone—systemic scleroderma	4.5e-05	0.000218	CcSEcCtD
Propafenone—Pain—Methotrexate—systemic scleroderma	4.48e-05	0.000217	CcSEcCtD
Propafenone—Pruritus—Prednisone—systemic scleroderma	4.44e-05	0.000215	CcSEcCtD
Propafenone—Feeling abnormal—Methotrexate—systemic scleroderma	4.32e-05	0.000209	CcSEcCtD
Propafenone—Diarrhoea—Prednisone—systemic scleroderma	4.29e-05	0.000208	CcSEcCtD
Propafenone—Gastrointestinal pain—Methotrexate—systemic scleroderma	4.29e-05	0.000208	CcSEcCtD
Propafenone—Urticaria—Methotrexate—systemic scleroderma	4.16e-05	0.000202	CcSEcCtD
Propafenone—Dizziness—Prednisone—systemic scleroderma	4.15e-05	0.000201	CcSEcCtD
Propafenone—Body temperature increased—Methotrexate—systemic scleroderma	4.14e-05	0.000201	CcSEcCtD
Propafenone—Abdominal pain—Methotrexate—systemic scleroderma	4.14e-05	0.000201	CcSEcCtD
Propafenone—Vomiting—Prednisone—systemic scleroderma	3.99e-05	0.000193	CcSEcCtD
Propafenone—Rash—Prednisone—systemic scleroderma	3.95e-05	0.000192	CcSEcCtD
Propafenone—Dermatitis—Prednisone—systemic scleroderma	3.95e-05	0.000192	CcSEcCtD
Propafenone—Headache—Prednisone—systemic scleroderma	3.93e-05	0.000191	CcSEcCtD
Propafenone—Hypersensitivity—Methotrexate—systemic scleroderma	3.86e-05	0.000187	CcSEcCtD
Propafenone—Asthenia—Methotrexate—systemic scleroderma	3.76e-05	0.000182	CcSEcCtD
Propafenone—Nausea—Prednisone—systemic scleroderma	3.72e-05	0.000181	CcSEcCtD
Propafenone—Pruritus—Methotrexate—systemic scleroderma	3.71e-05	0.00018	CcSEcCtD
Propafenone—Diarrhoea—Methotrexate—systemic scleroderma	3.59e-05	0.000174	CcSEcCtD
Propafenone—Dizziness—Methotrexate—systemic scleroderma	3.47e-05	0.000168	CcSEcCtD
Propafenone—Vomiting—Methotrexate—systemic scleroderma	3.33e-05	0.000162	CcSEcCtD
Propafenone—Rash—Methotrexate—systemic scleroderma	3.3e-05	0.00016	CcSEcCtD
Propafenone—Dermatitis—Methotrexate—systemic scleroderma	3.3e-05	0.00016	CcSEcCtD
Propafenone—Headache—Methotrexate—systemic scleroderma	3.28e-05	0.000159	CcSEcCtD
Propafenone—Nausea—Methotrexate—systemic scleroderma	3.11e-05	0.000151	CcSEcCtD
